

Aden Ka-Yin Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2001173/publications.pdf>

Version: 2024-02-01

31
papers

1,223
citations

394421

19
h-index

414414

32
g-index

32
all docs

32
docs citations

32
times ranked

2294
citing authors

#	ARTICLE	IF	CITATIONS
1	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. <i>Frontiers in Oncology</i> , 2022, 12, 839302.	2.8	3
2	Low-grade BRAF V600E mutant oligodendroglioma-like tumors of children may show EGFR and MET amplification. <i>Brain Pathology</i> , 2021, 31, 211-214.	4.1	2
3	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. <i>Modern Pathology</i> , 2021, 34, 1245-1260.	5.5	21
4	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106882.	1.4	1
5	Establishment and characterization of meningioma patient-derived organoid. <i>Journal of Clinical Neuroscience</i> , 2021, 94, 192-199.	1.5	9
6	STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. <i>Molecular Cancer</i> , 2021, 20, 147.	19.2	13
7	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. <i>Brain Pathology</i> , 2020, 30, 541-553.	4.1	73
8	Clinical and mutational profiles of adult medulloblastoma groups. <i>Acta Neuropathologica Communications</i> , 2020, 8, 191.	5.2	30
9	FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. <i>Oncogene</i> , 2019, 38, 33-46.	5.9	41
10	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz015.	0.7	22
11	SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. <i>Oncogene</i> , 2018, 37, 1159-1174.	5.9	36
12	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. <i>Journal of Neuro-Oncology</i> , 2018, 139, 307-322.	2.9	2
13	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. <i>Laboratory Investigation</i> , 2018, 98, 968-976.	3.7	33
14	Pediatric low-grade gliomas can be molecularly stratified for risk. <i>Acta Neuropathologica</i> , 2018, 136, 641-655.	7.7	36
15	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. <i>Laboratory Investigation</i> , 2017, 97, 946-961.	3.7	24
16	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. <i>Neuro-Oncology</i> , 2017, 19, 1008-1010.	1.2	12
17	Adult IDH wild-type lower-grade gliomas should be further stratified. <i>Neuro-Oncology</i> , 2017, 19, 1327-1337.	1.2	177
18	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—a meta-analysis of aggregate data. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 1-9.	4.4	44

#	ARTICLE	IF	CITATIONS
19	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
20	HG-07ABERRANTLY EXPRESSED microRNAs IN BRAF MUTATED YOUNG ADULT GBM. <i>Neuro-Oncology</i> , 2016, 18, iii49.2-iii49.	1.2	1
21	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. <i>Oncotarget</i> , 2016, 7, 64615-64630.	1.8	22
22	<i>p53</i> and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2016, 375, 2206-2208.	27.0	16
23	Biomarker-based prognostic stratification of young adult glioblastoma. <i>Oncotarget</i> , 2016, 7, 5030-5041.	1.8	45
24	Combination genetic signature stratifies lower-grade gliomas better than histological grade. <i>Oncotarget</i> , 2015, 6, 20885-20901.	1.8	42
25	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. <i>Modern Pathology</i> , 2015, 28, 177-186.	5.5	107
26	TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. <i>Oncotarget</i> , 2015, 6, 24871-24883.	1.8	34
27	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11485-94.	0.5	11
28	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. <i>Modern Pathology</i> , 2014, 27, 332-342.	5.5	45
29	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 8627-36.	0.5	24
30	MIR-137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets CSE1L. <i>Brain Pathology</i> , 2013, 23, 426-439.	4.1	39
31	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. <i>PLoS ONE</i> , 2013, 8, e67421.	2.5	25